NCT00616031Unknown2 期
A Phase II, Multinational and Multicenter, Randomized, Controlled Study of Paclitaxel and Carboplatin With vs Without Nitroglycerin in Patients With Untreated Advanced Non-small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 150
- 试验地点
- 2
- 主要终点
- Tumor response rate
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Nitroglycerin may help carboplatin and paclitaxel work better by making tumor cells more sensitive to the drugs.
PURPOSE: This phase II randomized trial is studying how well giving nitroglycerin together with paclitaxel and carboplatin works and compares it to giving paclitaxel and carboplatin alone in treating patients with previously untreated stage III or stage IV non-small cell lung cancer.
详细描述
OBJECTIVES:
- To evaluate tumor response rate and safety of nitroglycerin as a potentiator of anticancer combination therapy comprising paclitaxel and carboplatin in patients with previously untreated stage IIIB or IV non-small cell lung cancer.
OUTLINE: This is a multicenter, randomized, controlled study. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive nitroglycerin, paclitaxel, and carboplatin.
- Arm II: Patients receive paclitaxel and carboplatin. In both arms, treatment continues for 6 courses in the absence of disease progression or unacceptable toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Tumor response rate
次要结局
- Progression-free survival
- Adverse event and its severity
- Overall survival
- Change in the plasma concentration of VEGF between before and after the three-day administration of nitroglycerin prior to the start of the administration of anticancer drugs in the first course of the treatment
- Change in the number of endothelial progenitor cells in blood between before and after the three-day administration of nitroglycerin prior to the start of the administration of anticancer drugs in the first course of the treatment
- Blood concentration of paclitaxel and carboplatin immediately and two hours after the administration of the anticancer drug (paclitaxel) in the first course of treatment
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerFallopian Tube CancerPeritoneal Cavity CancerOvarian CancerNCT00331422Masonic Cancer Center, University of Minnesota7
已完成
2 期
Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell CancerKidney CancerNCT00077129Eastern Cooperative Oncology Group22
已完成
2 期
Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by SurgeryCervical CancerNCT01229930University of Glasgow130
终止
2 期
Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast CancerRecurrent Breast CancerStage IV Breast CancerBreast CancerNCT01009983Wake Forest University Health Sciences14
已完成
2 期
S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerLung CancerNCT00085501SWOG Cancer Research Network242